Avadel Pharmaceuticals plc (AVDL)

NASDAQ: AVDL · IEX Real-Time Price · USD

13.89

-0.23 (-1.63%)

At close: Jul 2, 2024, 4:00 PM

13.35

-0.54 (-3.89%)

After-hours: Jul 2, 2024, 5:49 PM EDT

Avadel Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2000
Net Income	-160.28	-137.46	-77.33	7.03	-33.23	Upgrade
Depreciation & Amortization	1.77	1.49	0.82	1.69	2.49	Upgrade
Share-Based Compensation	15.81	7.01	8.87	3	0.52	Upgrade
Other Operating Activities	14.19	58.65	-9.67	-60.45	-8.1	Upgrade
Operating Cash Flow	-128.51	-70.3	-77.31	-48.73	-38.33	Upgrade
Capital Expenditures	0	-0.72	-0.03	-0.1	0.13	Upgrade
Acquisitions	0	0	16.5	25.5	0	Upgrade
Change in Investments	-50.09	80.41	40.46	-95.12	38.6	Upgrade
Investing Cash Flow	-50.09	79.7	56.93	-69.72	38.72	Upgrade
Share Issuance / Repurchase	148.36	28	0.26	179.68	0.12	Upgrade
Debt Issued / Paid	-13.02	-13.46	0	0	0	Upgrade
Other Financing Activities	-	-	-	-	-0.15	Upgrade
Financing Cash Flow	135.34	14.54	0.26	179.68	-0.03	Upgrade
Exchange Rate Effect	0.46	-0.66	-0.9	0.72	0.08	Upgrade
Net Cash Flow	-42.81	23.27	-21.01	61.95	0.45	Upgrade
Free Cash Flow	-128.51	-71.02	-77.34	-48.83	-38.2	Upgrade
Free Cash Flow Margin	-459.58%	-	-	-218.64%	-64.51%	Upgrade
Free Cash Flow Per Share	-1.60	-1.18	-1.32	-0.92	-1.02	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).